GlassScriptPhysician profile
Adrian Felder
NPI 1518435197
$88,714.46
in general payments reported to CMS, 2019-2025
24 companies · $28K in 2025
The $28K reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,392 · 2022: $11K · 2023: $17K · 2024: $28K · 2025: $28K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $26K · Consulting Fee: $24K · Travel and Lodging: $17K · Food and Beverage: $7,320 · Education: $156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $25,908.00 |
| Consulting Fee | $23,784.56 |
| Travel and Lodging | $16,609.32 |
| Food and Beverage | $7,320.18 |
| Education | $156.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $41,982.39 | 2021-2025 | Tyvaso, Remodulin, Orenitram |
| Johnson & Johnson Health Care Systems INC. | $20,763.07 | 2023-2025 | Opsumit, Uptravi, Veletri |
| Bayer Healthcare Pharmaceuticals INC. | $11,705.35 | 2021-2025 | |
| Actelion Pharmaceuticals US, INC. | $8,724.88 | 2021-2025 | Uptravi, Opsumit, Opsynvi |
| Merck Sharp & Dohme LLC | $3,948.01 | 2021-2025 | Winrevair |
| Abbott Laboratories | $334.41 | 2021-2023 | Cardiomems |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $254.38 | 2021-2023 | Lifevest |
| Amgen INC. | $121.22 | 2023-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $110.80 | 2021-2024 | Xarelto |
| Novo Nordisk INC | $105.16 | 2022-2024 | Ozempic |
| Sandoz INC. | $99.37 | 2023-2024 | Treprostinil |
| Novartis Pharmaceuticals Corporation | $96.18 | 2021-2023 | |
| Atricure, INC. | $92.79 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $92.32 | 2021-2025 | |
| Recor Medical INC | $42.99 | 2025 | Paradise Ultrasound Renal Denervation System |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $39.34 | 2022 | |
| Esperion Therapeutics, INC. | $37.50 | 2023-2024 | Nexletol |
| Pfizer INC. | $36.53 | 2023 | |
| Alnylam Pharmaceuticals INC. | $28.96 | 2023 | Onpattro |
| Baxter Healthcare | $21.30 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Amarin Pharma, INC. | $21.00 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.89 | 2024 | |
| Idorsia Pharmaceuticals US INC | $18.87 | 2025 | Tryvio |
| Liquidia Technologies, INC. | $16.75 | 2025 | Yutrepia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adrian Felder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.